Cornerstone Capital Management Holdings LLC. grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 536.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,046 shares of the medical instruments supplier’s stock after buying an additional 47,246 shares during the quarter. Cornerstone Capital Management Holdings LLC. owned approximately 0.08% of West Pharmaceutical Services worth $5,394,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in WST. Artisan Partners Limited Partnership acquired a new stake in West Pharmaceutical Services in the 3rd quarter worth approximately $81,059,000. BlackRock Inc. lifted its holdings in West Pharmaceutical Services by 7.1% in the 2nd quarter. BlackRock Inc. now owns 6,217,894 shares of the medical instruments supplier’s stock worth $587,715,000 after purchasing an additional 412,858 shares during the last quarter. Koch Industries Inc. lifted its holdings in West Pharmaceutical Services by 14,908.3% in the 2nd quarter. Koch Industries Inc. now owns 413,028 shares of the medical instruments supplier’s stock worth $409,000 after purchasing an additional 410,276 shares during the last quarter. TCW Group Inc. acquired a new stake in West Pharmaceutical Services in the 3rd quarter worth approximately $30,348,000. Finally, Renaissance Technologies LLC lifted its holdings in West Pharmaceutical Services by 7,670.7% in the 2nd quarter. Renaissance Technologies LLC now owns 318,600 shares of the medical instruments supplier’s stock worth $30,114,000 after purchasing an additional 314,500 shares during the last quarter. Institutional investors and hedge funds own 93.28% of the company’s stock.
Several research firms recently weighed in on WST. Stephens began coverage on West Pharmaceutical Services in a report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 target price for the company. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Wednesday, September 27th. Wells Fargo & Company upped their price target on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Bank of America lowered West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price target for the company. in a report on Tuesday, October 17th. Finally, Jefferies Group upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their price target for the stock from $96.00 to $115.00 in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. West Pharmaceutical Services currently has a consensus rating of “Hold” and a consensus target price of $106.00.
Shares of West Pharmaceutical Services, Inc. (NYSE WST) traded down $0.50 during mid-day trading on Friday, hitting $98.24. The stock had a trading volume of 223,500 shares, compared to its average volume of 359,739. West Pharmaceutical Services, Inc. has a one year low of $77.97 and a one year high of $103.36. The firm has a market capitalization of $7,331.73, a price-to-earnings ratio of 42.56, a PEG ratio of 2.11 and a beta of 1.11. The company has a current ratio of 2.59, a quick ratio of 1.87 and a debt-to-equity ratio of 0.15.
West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.14. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The company had revenue of $398.20 million during the quarter, compared to analyst estimates of $386.02 million. During the same period in the previous year, the company earned $0.53 earnings per share. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. equities analysts expect that West Pharmaceutical Services, Inc. will post 2.76 EPS for the current fiscal year.
In other news, CFO William J. Federici sold 21,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $99.01, for a total transaction of $2,079,210.00. Following the completion of the transaction, the chief financial officer now directly owns 190,493 shares in the company, valued at $18,860,711.93. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.90% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Cornerstone Capital Management Holdings LLC. Increases Stake in West Pharmaceutical Services, Inc. (WST)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/15/cornerstone-capital-management-holdings-llc-increases-stake-in-west-pharmaceutical-services-inc-wst.html.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.